Blocking Dot1L Enzyme Halts Stress-Driven Heart Enlargement in Mice
A histone-modifying enzyme called Dot1L drives pathological cardiac hypertrophy via a newly identified epigenetic pathway — and blocking it works in mice.
Summary
Pathological cardiac hypertrophy — when the heart muscle enlarges abnormally under stress — is a major precursor to heart failure, yet treatment options remain limited. Researchers discovered that an enzyme called Dot1L, which adds chemical tags to histones (the protein spools DNA wraps around), becomes overactive in stressed heart cells. This drives the expression of a transcription factor called Tbx6, which amplifies the harmful enlargement. Mice genetically engineered to lack Dot1L in heart muscle were protected from pressure-overload-induced hypertrophy. Crucially, a small-molecule drug called SGC0946 that inhibits Dot1L also reduced hypertrophy in mice. This identifies the Dot1L–H3K79me2–Tbx6 axis as a novel epigenetic target and raises the prospect of new drug therapies for the millions at risk of heart failure.
Detailed Summary
Heart failure remains one of the leading causes of death worldwide, and pathological cardiac hypertrophy — the abnormal thickening of heart muscle in response to chronic stress — is a critical step on that path. Despite decades of research, no therapies directly target the epigenetic mechanisms that lock the heart into this destructive remodeling program.
This study investigated the role of Dot1L, a histone methyltransferase that specifically dimethylates histone H3 at lysine 79 (H3K79me2). Using mass spectrometry-based histone profiling, the researchers found that H3K79 dimethylation and Dot1L protein levels were elevated in hypertrophic cardiomyocytes, in hearts subjected to pressure overload via transverse aortic constriction or isoproterenol infusion, and in tissue from human patients with hypertrophic cardiomyopathy.
To establish causation, the team generated cardiomyocyte-specific Dot1L knockout mice, which were protected against pressure-overload-induced hypertrophy compared to controls. Conversely, cardiomyocyte-specific Dot1L overexpression worsened hypertrophy. RNA sequencing and chromatin immunoprecipitation sequencing identified Tbx6, a T-box transcription factor, as a direct downstream target of Dot1L-mediated H3K79 dimethylation. Knocking down Tbx6 abolished the pro-hypertrophic effects of Dot1L overexpression, placing Tbx6 squarely in the pathway.
Pharmacologically, treatment with SGC0946 — a selective Dot1L inhibitor — markedly reduced isoproterenol-induced cardiac hypertrophy in mice, demonstrating therapeutic tractability. This positions Dot1L inhibition as a potentially druggable strategy for heart failure prevention.
Caveats include that all mechanistic and pharmacological findings are in rodents, and the role of Tbx6 in adult human cardiac pathology is not yet established. The summary is based on the abstract only, so mechanistic detail and quantitative data from the full paper are not available. Translational studies are needed before this pathway can be pursued clinically.
Key Findings
- Dot1L and H3K79 dimethylation are upregulated in hypertrophic hearts of mice and human patients with hypertrophic cardiomyopathy.
- Cardiomyocyte-specific Dot1L knockout mice are protected from pressure-overload-induced cardiac hypertrophy.
- Dot1L drives hypertrophy by epigenetically activating the transcription factor Tbx6 in stressed cardiomyocytes.
- The Dot1L inhibitor SGC0946 significantly reduced isoproterenol-induced cardiac hypertrophy in mice.
- Knocking down Tbx6 abolished Dot1L-overexpression-driven hypertrophy, confirming Tbx6 as the key downstream effector.
Methodology
The study combined cardiomyocyte-specific knockout and transgenic mouse models with two stress induction protocols (transverse aortic constriction and isoproterenol infusion). Histone modifications were profiled by nano-HPLC-MS/MS; downstream targets were identified by integrating RNA sequencing with chromatin immunoprecipitation sequencing. Primary neonatal rat ventricular myocytes and a pharmacological inhibitor (SGC0946) were used to validate mechanistic and therapeutic findings.
Study Limitations
All causal and pharmacological experiments were conducted in rodent models; direct relevance to human cardiac hypertrophy requires validation in larger animal models and clinical cohorts. The downstream role of Tbx6 in adult human cardiomyocytes is inferred from mouse and neonatal rat data and has not been confirmed in adult human tissue. This summary is based on the abstract only, as the full text was not available, limiting assessment of statistical rigor and effect sizes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: